Our multidisciplinary centre for MND is located in Modena, at the intersection between Northern and Central Italy. Our team follows 250-300 patients/year providing extended care from the diagnosis to more advanced phases of the disease and supports basic and clinical research with an expertise in leading epidemiological studies and phase II clinical trials.
Following a large number of patients from the province and regional surroundings with a wide multidisciplinary team, this center coordinates Emilia Romagna population-based Register for ALS bringing forward epidemiological research. We collaborate with other national and international institutes to develop multicentric projects for clinical research; besides participating to several trials we currently lead three Italian RCT. A neurobiobank allows to store high-quality and deeply phenotyped samples together with a fully equipped laboratory for molecular biology, cell biology and genetics. The center is included in ITALSGEN Consortium for genetic research and actively collaborate with University of Modena on translational ALS projects and on epidemiological studies. The core of our research team is represented by 4 MND consultants, a data manager, 2 research nurses, a biologist; the local Statistics Unit grants full support for data analysis. Other facilities includes a fully equipped clinical neurophysiology laboratory, a neuropsychology unit and 3T GE system MRI.
| AOU Modena ALS Centre | |
|---|---|
| Foundation year | 2000 |
| Director | Jessica Mandrioli |
| Principal investigator | Jessica Mandrioli |
| Contact information | |
|---|---|
| Address | Via Pietro Giardini 1355, |
| Contact | Jessica Mandrioli |
| Phone | +390593961640 |
| Mandrioli.jessica@aou.mo.it | |
| Website | Visit the website |
Publications
- Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers. Zucchi E, Bonetto V, Sorarù G, Martinelli I, Parchi P, Liguori R, Mandrioli J. Mol Neurodegener. 2020 Oct 15;15(1):58.
- The NGS technology for the identification of genes associated with the ALS. A systematic review. Pecoraro V, Mandrioli J, Carone C, Chiò A, Traynor BJ, Trenti T. Eur J Clin Invest. 2020 May;50(5):e13228.
- A novel p.N66T mutation in exon 3 of the SOD1 gene: report of two families of ALS patients with early cognitive impairment. Martinelli I, Zucchi E, Gessani A, Fini N, Chiò A, Pecoraro V, Trenti T, Mandrioli J. Amyotroph Lateral Scler Frontotemporal Degener. 2020 May;21(3-4):296-300.
- FETR-ALS Study Protocol: A Randomized Clinical Trial of Fecal Microbiota Transplantation in Amyotrophic Lateral Sclerosis. Mandrioli J, Amedei A, Cammarota G, Niccolai E, Zucchi E, D’Amico R, Ricci F, Quaranta G, Spanu T, Masucci L. Front Neurol. 2019 Sep 20;10:1021.
- Comparative Analysis of C9orf72 and Sporadic Disease in a Large Multicenter ALS Population: The Effect of Male Sex on Survival of C9orf72 Positive Patients. Trojsi F, Siciliano M, Femiano C, Santangelo G, Lunetta C, Calvo A, Moglia C, Marinou K, Ticozzi N, Ferro C, Scialò C, Sorarù G, Conte A, Falzone YM, Tortelli R, Russo M, Sansone VA, Chiò A, Mora G, Silani V, Volanti P, Caponnetto C, Querin G, Sabatelli M, Riva N, Logroscino G, Messina S, Fasano A, Monsurrò MR, Tedeschi G, Mandrioli J. Front Neurosci. 2019 May 17;13:485.
For other publications, see: https://pubmed.ncbi.nlm.nih.gov/?term=ALS+Modena&sort=date&size=200
Restricted information
| Serving population | |
|---|---|
| Serving population | Modena: 700000; Emilia Romagna: 4500000 |
| Patient resources | |
|---|---|
| Population based register | Yes |
| Clinic based register | Yes |
| Geographically matched controls | Yes |
| Number of skin samples | 60 |
Banks
| Type | ALS Patients | Controls | Other |
|---|---|---|---|
| DNA Bank | |||
| Serum Bank | |||
| RNA Bank |
| Research activities | |
|---|---|
| Clinical management research | Yes |
| Neuro epidemiology | Yes |
| Neuro physiology | Yes |
| Neuro imaging | Yes |
| Neuro psychology | Yes |
| Neuro pathology | No |
| Genomics | Yes |
| Transcriptomics | Yes |
| Metabolomics | Yes |
Clinical Trials - Industry sponsored
| Name | Type | Patients |
|---|---|---|
| ALXN1210-ALS-308 | Phase III randomized, double blind, placebo controlled , multicenter CT | 354 |
| RNS60 | Phase II randomized, double blind, placebo controlled , multicenter CT | 160 |
Clinical Trials - Investigator initiated
| Name | Type | Patients |
|---|---|---|
| RAP-ALS | Phase II randomized, double blind, placebo controlled , multicenter CT | 63 |
| CO-ALS | Phase II randomized, double blind, placebo controlled , multicenter CT | 54 |
| FETR-ALS | randomized, double blind, controlled, multicenter CT, testing fecal microbiota transplantation in ALS | 42 |